OICR-9429

Antagonist of WDR5

Structure

Information

  • WDR5
  • Antagonist
  • 500 nM - 5 uM

In Vitro Validations

Uniprot ID: P61964
Target Class: Structural protein
Target SubClass: WD40-repeat proteins
Potency: Kd
Potency Value: 93 nM
Potency Assay: ITC OICR-9429 disrupts WDR5 interaction with a peptide from WDR5-interacting protein Kdisp = 64 nM.
PDB ID for probe-target interaction (3D structure): 4E5G
Target aliases:
WD repeat-containing protein 5, BIG3, WDR5, WDR5_H ...

DOI Reference: 10.1038/nchembio.1859

In Cell Validations

In Vivo Data

No in Vivo Validations

Off-Target Selectivity Assesments

Potency assay (off target): No activity detected against 9 WDR40 or epigenetic reader proteins.
Probe Selectivity in Vitro:

No binding or inhibition was detected against 22 protein methyltransferases. Negligible activity was detected against >250 human kinases, GPCRs, ion channels (Cerep) at 1 uM.

I have extra information to add

SERP ratings and comments


SERP Ratings

In Cell Rating

(last updated: 17 May 2016 )

SERP Ratings

In Cell Rating

SERP Comments:

OICR-9429 is a small-molecule antagonist of the WDR5-MLL protein-protein interaction, a notoriously difficult class of molecular targets. There is solid evidence showing a direct in vitro interaction between OICR-9429 and its intended target, WDR5. This includes ITC and X-ray crystallography. This compound displays high affinity (Kd <100 nM) for WDR5. It has well-characterized, reversible binding kinetics. The authors also show (at least in vitro) that it does not significantly inhibit other many other HMTs, kinases or other pharmacologically relevant targets. There are convincing target-engagement data in cells via biotinylated pull-down proteomics and gene-expression profiling consistent with such engagement. It is effective in vitro versus p30-expressing cells. Note, there is <1-log difference is cytotoxicity of OICR-9429 to p30-expressing cells versus other cells, as reported in the original publication. Therefore, dosage of this probe should be carefully considered, perhaps even taking care to perform dose-response controls to rule out non-specific effects that may occur at higher compound concentrations. Users should take advantage of a close structural analog, OICR-0547, as a negative control compound. The authors present evidence showing the negative control compound does not disrupt the WDR5-MLL interaction in vitro. It has similar cytotoxoicity as OICR-9429 versus K562 cells. Users should also note that there is only ~1-log difference in cytotoxicity between the active compound and inactive analog.

(last updated: 18 May 2016 )

SERP Ratings

In Cell Rating
In Model Organisms

SERP Comments:

Recommended concentration is based on the finding that the IC50s for the disruption of WDR5-MLL and WDR5-RbBP5 complexes in co-IPs from HEK293 expressing Flag-WDR5 are 223 nM and 458 nM, respectively.

(last updated: 20 Jun 2016 )